Interview Bert Arjan Millenaar with Paul van Liempt

https://nlc-health.webflow.io/news/interview-bert-arjan-millenaar-with-paul-van-liempt

Anne Reijns

Jun 2019

•

5 min read

Anne Reijns

Jun 2019

•

5 min read

Read article on external website

Interview (in Dutch but subtitled in English) with Paul van Liempt, explaining the NLC – The Healthtech Venture Builder way of bringing science to life.

Insights

Introducing DiaphOne Therapeutics: Developing small molecule antagonists

Introducing DiaphOne Therapeutics: Developing small molecule antagonists

The power of additionality: Why impact investing should focus on building companies that otherwise wouldn’t exist

The power of additionality: Why impact investing should focus on building companies that otherwise wouldn’t exist

Innovation and collaboration is the cure to solving the healthcare crisis

Innovation and collaboration is the cure to solving the healthcare crisis

Derisking early-stage investments to solve global healthcare challenges

Derisking early-stage investments to solve global healthcare challenges

NLC & HMG launch the Global Open Challenge!

NLC & HMG launch the Global Open Challenge!

NLC Health Ventures and HMG are announcing partnership to accelerate global health tech innovations

NLC Health Ventures and HMG are announcing partnership to accelerate global health tech innovations

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514

SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514

Introducing Exolvo: NLC Health Ventures launches new early-stage drug delivery company

Introducing Exolvo: NLC Health Ventures launches new early-stage drug delivery company

Dutch health insurer VGZ invests in NLC Health Ventures

Dutch health insurer VGZ invests in NLC Health Ventures

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted

NLC venture Altach secures €1.2 million investment to transform treatments for cartilage injuries

NLC venture Altach secures €1.2 million investment to transform treatments for cartilage injuries

NLC completes first close of €100 million health impact fund

NLC completes first close of €100 million health impact fund

AI Healthtech start-up MindAffect raises €1.1 million to transform hearing diagnostics

AI Healthtech start-up MindAffect raises €1.1 million to transform hearing diagnostics

IPD secures funding of €2.1 million to initiate its first-in-human trials for prosthetic joint infections

IPD secures funding of €2.1 million to initiate its first-in-human trials for prosthetic joint infections

Introducing Aerion Bioscience: A new era of cancer screening

Introducing Aerion Bioscience: A new era of cancer screening

CUIP and NLC Health Ventures signed a MoU to bring cutting-edge innovations to life

CUIP and NLC Health Ventures signed a MoU to bring cutting-edge innovations to life

POROUS wins innovation award

POROUS wins innovation award

Ansana secures a €850,000 investment

Ansana secures a €850,000 investment

Introducing LiftYa: Stability with motion

Introducing LiftYa: Stability with motion